Analysis of the clinical development landscape targeting long-COVID and evolution of clinical outcome assessment methods – An industry perspective

Article Sidebar

PDF
Published Mar 29, 2025
DOI: https://doi.org/10.18103/mra.v3i3.6320

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Ramesh Chandra Pandey
Real-World Evidence, IQVIA Consulting Services, Mumbai, India
Saurabh Kumar
Real-World Evidence, IQVIA Consulting Services, Mumbai, India

Abstract

Long-COVID is the term used for health complications seen in patients recovered from acute coronavirus disease-19 (acute COVID-19) illness. The spectrum of clinical symptoms, involvement of various organ systems, and pathophysiological mechanisms have been reviewed extensively in the literature. The pharmaceutical industry has responded to the rising disease burden due to long-COVID through clinical trials addressing specific health concerns. For this analysis, we extracted the clinical trial data from the trial registry clinicaltrials.gov using keywords specific to long-COVID OR post-COVID or post-acute sequelae of COVID-19. This universe of 5146 trials was subjected to step-by-step screening to include industry-sponsored clinical studies addressing long-COVID. We analyzed 74 long-COVID-related clinical trial activities by the pharmaceutical industry as a landscape for the evolution of the trends, clinical outcome assessment methods, and future directions. There are nearly 100 clinical studies conducted to address long-COVID since the pandemic so far. Year by year, consistent investment by pharmaceutical companies suggests that the industry recognizes the unmet needs in this field. An overview of innovative approaches in the landscape, like novel biologic products and medical technologies, has been captured. The investigators have addressed the complexity of health complications through novel assessment methods such as patient-reported outcomes (PRO) and post-COVID related functional assessment scales. Here, we highlight the top PROs and functional scales being used in these clinical studies. The lack of a specific diagnosis method remains the currently unsolved puzzle, and a prerequisite for further research and clinical development in this space.

Keywords: Long COVID, Post-COVID-19, Post-COVID Syndrome, Clinical development, Clinical outcomes, Industry

Article Details

How to Cite
PANDEY, Ramesh Chandra; KUMAR, Saurabh. Analysis of the clinical development landscape targeting long-COVID and evolution of clinical outcome assessment methods – An industry perspective. Medical Research Archives, [S.l.], v. 13, n. 3, mar. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6320>. Date accessed: 06 apr. 2025. doi: https://doi.org/10.18103/mra.v3i3.6320.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 13 No 3 (2025): Vol.13, Issue 3, March 2025
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Park MB, Ranabhat CL. COVID-19 trends, public restrictions policies and vaccination status by economic ranking of countries: a longitudinal study from 110 countries. Arch Public Health 2022; 80(1):197. DOI: 10.1186/s13690-022-00936-w.

2. Thakur I, Chatterjee A, Ghosh AK, et al. A comparative study between first three waves of COVID-19 pandemic with respect to risk factors, initial clinic-demographic profile, severity and outcome. J Family Med Prim Care 2024;13(6):2455-2461. DOI: 10.4103/jfmpc.jfmpc_1884_23.

3. Bali Swain R, Lin X, Wallentin FY. COVID-19 pandemic waves: Identification and interpretation of global data. Heliyon 2024;10(3):e25090. DOI: 10.1016/j.heliyon.2024.e25090.

4. Umesh A, Pranay K, Pandey RC, Gupta MK. Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism. Infection 2022;50(5):1053-1066. DOI: 10.1007/s15010-022-01835-6.

5. Sivan M, Preston N, Parkin A, et al. The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome. J Med Virol 2022;94(9):4253-4264. DOI: 10.1002/jmv.27878.

6. Chharia A, Jeevan G, Jha RA, Liu M, Berman JM, Glorioso C. Accuracy of US CDC COVID-19 forecasting models. Front Public Health 2024;12: 1359368. DOI: 10.3389/fpubh.2024.1359368.

7. USFDA. FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years. FDA News Release 2020
(https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-group-rare-blood-disorders-nearly-14-years).

8. Lamb YN, Syed YY, Dhillon S. Immune Globulin Subcutaneous (Human) 20% (Hizentra((R))): A Review in Chronic Inflammatory Demyelinating Polyneuropathy. CNS Drugs 2019;33(8):831-838. DOI: 10.1007/s40263-019-00655-x.

9. Bian H, Chen L, Zheng ZH, et al. Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial. Signal Transduct Target Ther 2023;8(1):46. DOI: 10.1038/s41392-023-01323-9.

10. Kanegane H, Imai K, Yamada M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol 2014; 34(2):204-11. DOI: 10.1007/s10875-013-9985-z.

11. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594(7862):259-264. DOI: 10.103 8/s41586-021-03553-9.

12. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis 2022;226(9):1593-1607. DOI: 10.1093/infdis/jiac136.

13. Franco JVA, Garegnani LI, Metzendorf MI, Heldt K, Mumm R, Scheidt-Nave C. Post-covid-19 conditions in adults: systematic review and meta-analysis of health outcomes in controlled studies. BMJ Med 2024;3(1):e000723. DOI: 10.1136/bmjmed-2023-000723.

14. Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022;10(9):863-876. DOI: 10.1016/S22 13-2600(22)00126-6.

15. Kaur H, Chauhan A, Mascarenhas M. Does SARS Cov-2 infection affect the IVF outcome - A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2024;292:147-157. DOI: 10.1 016/j.ejogrb.2023.11.027.

16. Tanriverdi O, Alkan A, Karaoglu T, Kitapli S, Yildiz A. COVID-19 and Carcinogenesis: Exploring the Hidden Links. Cureus 2024;16(8):e68303. DOI: 10.7759/cureus.68303.

17. Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: A systematic review. Front Med (Lausanne) 2023;10: 1085988. DOI: 10.3389/fmed.2023.1085988.

18. Espin E, Yang C, Shannon CP, Assadian S, He D, Tebbutt SJ. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine 2023;91:104552. DOI: 10.1016/j.ebiom.2023.104552.

19. Thomas C, Faghy MA, Chidley C, Phillips BE, Bewick T, Ashton RE. Blood Biomarkers of Long COVID: A Systematic Review. Mol Diagn Ther 2024; 28(5):537-574. DOI: 10.1007/s40291-024-00731-z.

20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121-3. DOI: 10.1001/archneur.1989.00520460115022.

21. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54(7):581-6. DOI: 10.1136/thx.54.7.581.

22. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993;37(2):147-53. DOI: 10.1016/0022-3999(93) 90081-p.

23. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord 2009;114(1-3):163-73. DOI: 10.1016 /j.jad.2008.06.026.

24. Yar T, Salem AM, Rafique N, et al. Composite Autonomic Symptom Score-31 for the diagnosis of cardiovascular autonomic dysfunction in long-term coronavirus disease 2019. J Family Community Med 2024;31(3):214-221. DOI: 10.4103/jfcm.jfcm_20_24.

25. Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score. Mayo Clin Proc 2012;87(12):1196-201. DOI: 10.1016/j.mayoc p.2012.10.013.

26. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003;54(4):345-52. DOI: 10.1016/s0022-3999 (02)00392-6.

27. de Jong CMM, Le YNJ, Boon G, Barco S, Klok FA, Siegerink B. Eight lessons from 2 years of use of the Post-COVID-19 Functional Status scale. Eur Respir J 2023;61(5). DOI: 10.1183/13993003.0 0416-2023.

28. Mamyrbaev A, Turmukhambetova A, Bermagambetova S, et al. Assessing psychometric challenges and fatigue during the COVID-19 pandemic. J Med Life 2023;16(10):1527-1533. DOI: 10.25122/jml-2023-0244.